A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501, a First-in-class NK Cell Engager, in Patients with Relapsed And/or Refractory CD20-expressing Non-Hodgkin Lymphoma.

Lorenzo Falchi, Patricia Walker, Peter Presgrave,Gareth P. Gregory, Delphine Marie, A. J. Leyco,Olivier Demaria,Francois Le Floch, Wouter Hanekom,Cecile Bonin,Carine Paturel,Sonia Quaratino

Journal of Clinical Oncology（2024）

Cited 0|Views0

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined